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We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to
survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell
transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic
syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD pro-
phylaxis. There were no signiﬁcant differences in long-term survival after transplantation of PB and BM,
except for patients in ﬁrst chronic phase CML. For these patients, the 5-year rate of survival was lower after
transplantation of PB compared with transplantation of BM (35% versus 56%, P ¼ .001). Although mortality
risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P < .001) and BM (HR
1.73; P < .001) transplantations, its effect on mortality did not differ by graft type (P ¼ .42). BM is the preferred
graft for ﬁrst chronic phase CML, whereas as either graft is suitable for other leukemias.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Over the past decade, transplantation of peripheral blood
hematopoietic cells (PB) has increased and now accounts for
75% of unrelated adult donor transplantations. The results of
a phase III clinical trial that randomized 550 donors and their
recipients to receive either PB or bone marrow (BM) from
unrelated adult donors did not record signiﬁcant 2-year
survival differences between PB and BM transplantdgments on page 59.
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ty for Blood and Marrow Transplantation.recipients [1]. However, the incidence of chronic graft-
versus-host disease (GVHD) was higher and more severe
after PB transplantation, requiring a longer duration of
therapy compared with the incidence and severity after BM
transplantation. The effect of long-term outcomes was not
determined.
In HLA-matched sibling transplantation, long-term
follow-up did not demonstrate signiﬁcant survival differ-
ences between PB and BM transplantation for acute leukemia
[2,3]. However, there were differences in long-term survival
for those with chronic myeloid leukemia (CML) [2]. In that
report, compared with transplantation of BM, survival rates
were lower after transplantation of PB for patients who un-
derwent transplantation in ﬁrst chronic phase, but survival
Table 1
Characteristics of Patients, Diseases, and Transplantation
Characteristics BM PB P Value
No. of patients 1713 2463
Age, yr < .0001
18-29 501 (29%) 566 (23%)
30-39 393 (23%) 515 (21%)
40-49 473 (28%) 677 (27%)
50-59 295 (17%) 573 (23%)
60-70 51 (3%) 132 (5%)
Sex, male 940 (55%) 1366 (55%) .73
Performance score <.0001
90-100 1075 (63%) 1498 (61%)
< 90 440 (26%) 770 (31%)
Not reported 198 (12%) 195 (8%)
Recipient CMV serostatus .11
Positive 964 (56%) 1406 (57%)
Negative 738 (43%) 1026 (42%)
Not reported 11 (1%) 31 (1%)
Disease and disease status <.0001
Acute myeloid leukemia
First complete remission 258 (15%) 539 (22%)
Second complete remission 225 (13%) 329 (13%)
Relapse 299 (17%) 461 (19%)
Acute lymphoblastic leukemia
First complete remission 144 (8%) 256 (10%)
Second complete remission 149 (9%) 194 (8%)
Relapse 101 (6%) 151 (6%)
MDS
Refractory anemia 54 (3%) 92 (4%)
RAEB (>5% blasts in bone marrow) 91 (5%) 146 (6%)
CML
First chronic phase 238 (14%) 116 (5%)
Second chronic/accelerated phase 126 (7%) 143 (6%)
Blast phase 28 (2%) 36 (1%)
Donor-recipient HLA match .04
8/8 HLA-matched 1273 (74%) 1901 (77%)
7/8 HLA-matched 440 (26%) 562 (23%)
Donor-recipient ABO match <.0001
Matched 697 (41%) 927 (38%)
Minor mismatch 411 (24%) 499 (20%)
Major mismatch 491 (29%) 711 (29%)
Not reported 114 (7%) 326 (13%)
Donor-recipient sex match .14
Female donor, male recipient 282 (16%) 418 (17%)
Other 1414 (83%) 2003 (81%)
Not reported 17 (1%) 42 (2%)
Donor age, yr .73
18-32 706 (41%) 941 (38%)
33-50 806 (47%) 1051 (43%)
> 50 79 (5%) 116 (5%)
Not reported 122 (7%) 355 (14%)
Conditioning regimen <.0001
TBI þ cyclophosphamide 1016 (59%) 1098 (44%)
TBI þ other agents 55 (4%) 192 (8%)
Busulfan þ cyclophosphamide 482 (28%) 793 (32%)
Busulfan þ ﬂudarabine 160 (9%) 380 (15%)
GVHD prophylaxis <.0001
Tacrolimus-containing 1054 (62%) 1849 (75%)
Cyclosporine-containing 659 (38%) 614 (25%)
Cell dose per kilogram body weight <.0001
TNC <3  108/CD34 < 4.5  106 934 (55%) 350 (14%)
TNC  3  108/CD34  4.5  106 635 (37%) 1526 (62%)
Not reported 144 (8%) 587 (24%)
Transplantation period <.0001
2000-2004 1167(68%) 907 (37%)
2005-2008 546 (32%) 1556 (63%)
Follow-up, median (range), mo 73 (3-137) 61 (3-136)
CMV indicates cytomegalovirus; TBI, total body irradiation; TNC, total nucleated cells.
Data presented are n (%) unless otherwise indicated.
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more advanced disease [2].
In unrelated adult donor transplantations, it is uncertain
whether with longer follow-up, the recorded higher inci-
dence of chronic GVHD after PB transplantation will reducesurvival. Financial constraints limit the follow-up of clinical
trial recipients beyond the trial period, which is usually on
the order of 2 years and insufﬁcient to measure longer-term
outcomes. Therefore, using data reported to the Center for
International Blood and Marrow Transplant Research, we
Table 2
Probabilities of Nonrelapse Mortality, Relapse, and Overall Survival after PB
and BM Transplantation, Adjusted for Patient Age, Performance Score,
Cytomegalovirus Serostatus, Donor-Recipient HLA Match, ABO Match,
Conditioning Regimen, GVHD Prophylaxis, Donor Age, and Year of
Transplantation
No. of
Evaluable
BM/PB
Probability Estimate*
(95% CI)
P
Value
BM PB
Nonrelapse Mortality
AL CR1* 402/795 35% (30-40) 36% (32-40) .71
AL CR2* 374/523 41% (35-46) 36% (31-41) .22
AL relapse* 400/612 37% (32-41) 39% (35-43) .49
MDS RAy 54/92 36% (23-49) 48% (37-58) .21
MDS RAEB-1, RAEB-2y 91/146 31% (22-40) 44% (36-52) .04
CML CP1z 233/105 38% (32-45) 59% (49-70) .002
CML CP2, AP, BPz 154/179 40% (33-48) 37% (29-45) .57
Relapse
AL CR1* 402/795 30% (25-35) 29% (26-32) .75
AL CR2* 374/523 29% (25-34) 36% (31-40) .07
AL Relapse* 400/612 54% (49-59) 51% (48-56) .52
MDS RAy 54/92 13% (4-23) 18% (10-26) .45
MDS RAEB-1, RAEB-2y 91/146 43% (33-54) 23% (16-30) .003
CML CP1z 230/104 9% (5-13) 6% (1-11) .38
CML CP2, AP, BPz 154/179 27% (20-35) 34% (26-41) .23
Overall survival
AL CR1* 402/795 41% (36-47) 41% (37-45) .89
AL CR2* 374/523 32% (27-37) 31% (26-36) .79
AL relapse* 400/612 13% (9-16) 12% (9-15) .74
MDS RAy 54/92 53% (39-67) 38% (28-48) .10
MDS RAEB-1, RAEB 2y 91/146 31% (22-41) 31% (23-39) .99
CML CP1z 238/109 56% (50-62) 35% (26-45) .001
CML CP2, AP, BPz 154/179 42% (35-50) 33% (25-40) .07
CI indicates conﬁdence interval; AL, acute leukemia; CR, complete remis-
sion; RA, refractory anemia; CP, chronic phase; AP, accelerated phase; BP,
blast phase.
* Shown are the 7-year rates of nonrelapse mortality, relapse, and overall
survival for AL CR1, CR2, and relapse. Causes of death did not differ by graft
type; approximately 40% of patients in both groups died from recurrent
leukemia.
y Shown are the 5-year rates of nonrelapse mortality, relapse, and overall
survival for MDS RA, RAEB-1, and RAEB-2. BM recipients with RAEB-1 and
RAEB-2 were more likely to report death from recurrent disease compared
to PB recipients (37% versus 23%). Other causes of death did not differ by
graft type.
z Shown are the 5-year rates of nonrelapse mortality, relapse, and overall
survival for CML CP1, CP2, AP, and BP. Death from recurrent leukemia for
patients with CML CP1 was infrequent accounting for 5% of deaths in BM
recipients and 3% of deaths in PB recipients. Death from chronic GVHD
varied by graft type for patients with CML CP1; 26% in BM recipients
compared with 36% in PB recipients.
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in patients with hematologic malignancy.
PATIENTS AND METHODS
Patients
Included were patients ages 18 years and older with acute myeloid
leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome (MDS),
and CMLwho underwent transplantation in the United States between 2000
and 2008. Patients received PB or BM from adult unrelated donors whowere
HLA matched at the allele-level at HLA-A, -B, -C, and -DRB1 (n ¼ 3174) or
mismatched at a single HLA locus (n ¼ 1002). The transplantation-
conditioning regimens were myeloablative and GVHD prophylaxis
included either cyclosporine or tacrolimus. Myeloablative regimens were
deﬁned as containing a total body irradiation dose of 1000 cGy or higher, a
busulfan dose> 8mg/kg orally or> 6.5mg/kg intravenously, or a melphalan
dose > 150 mg/m2 [4]. Transplantations with ex vivo T celledepleted or
CD34-selected grafts were excluded. The median follow-up of PB recipients
was 5 years and that of BM recipients, 6 years.
Endpoints
The primary outcome was overall survival. Incidences of chronic GVHD
were based on reports from each transplantation center using standard
criteria [5]. Nonrelapse mortality was deﬁned as death not related to disease
recurrence, and relapse was deﬁned as disease recurrence based on
morphological, cytogenetic, or molecular evaluation. Death from any cause
was considered overall mortality and surviving patients were censored at
last follow-up.
Statistical Analysis
Patient, disease, and transplantation characteristics were compared
using chi-squared statistics for categorical variables. The probability of
chronic GVHD was calculated using the cumulative incidence estimator to
accommodate competing risks [6]. Probabilities of overall survival, non-
relapsemortality, and relapsewere computed by disease, disease status, and
graft type from Cox proportional hazard regression models [7], adjusted for
patient age, performance score, donor-recipient cytomegalovirus serostatus,
HLA match, ABO match, donor age, conditioning regimen, GVHD prophy-
laxis, and transplantation year. All analyses were performed using SAS,
version 9.3 (Cary, NC).
RESULTS
Patient, Disease, and Transplantation Characteristics
The characteristics of the study population are shown in
Table 1. There were differences in the characteristics of pa-
tients who received BM and PB. Recipients of PBwere slightly
older (median age, 42 versus 39 years), more likely to report
performance scores lower than 90, slightly more often HLA
matched to their donor but less likely to be blood group ABO
matched, more often received nonirradiation-containing
regimens, and more often received tacrolimus-containing
GVHD prophylaxis. PB recipients were less likely to have
CML. PB transplantations were more recent, with most
transplantations occurring after 2004.
Chronic GVHD
Chronic GVHD was signiﬁcantly higher after PB trans-
plantation compared with after BM transplantations
(hazard ratio [HR], 1.45; 95% conﬁdence interval, 1.32 to
1.59; P < .0001). Chronic GVHD was graded as extensive in
85% of PB recipients compared with 76% of BM recipients
(P < .0001). Although mortality risks were higher in pa-
tients with chronic GVHD after PB (HR, 1.58; P < .001) and
BM (HR, 1.73; P < .001) transplantations, its effect on
mortality did not differ by graft, despite the fact that
chronic GVHD after PB transplantations was more severe
(P ¼ .42).
Nonrelapse Mortality, Relapse, and Overall Survival
The probabilities of overall survival, nonrelapse mortality,
and relapse by disease and disease status, and adjusted
for patient age, performance score, donor-recipient cyto-megalovirus serostatus, HLA match, ABO match, donor age,
conditioning regimen, GVHD prophylaxis, and trans-
plantation year, factors associated with transplantation out-
comes in multivariate analysis, are shown in Table 2 and
Figures 1 to 3. For CML in ﬁrst chronic phase, outcomes were
also adjusted for tyrosine kinase inhibitor use before trans-
plantation. CD34 cell dose or total nucleated cell dose was
not associated with outcomes. For patients with acute leu-
kemia, therewere no signiﬁcant differences in 7-year rates of
overall survival, nonrelapse mortality, and relapse. Similarly,
for patients with early stage MDS there were no signiﬁcant
differences in rates of overall survival, nonrelapse mortality,
and relapse. However, for those who underwent trans-
plantationwith advanced stage MDS (refractory anemiawith
excess blasts [RAEB]), relapse rates were lower after PB
transplantations. There were signiﬁcant differences in long-
term survival by graft type for CML. Transplantation of PB
for those in ﬁrst chronic phase was associated with higher
rates of nonrelapse mortality and, consequently, lower rates
of survival.
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Figure 1. The 7-year probability of overall survival by disease status after PB
and BM transplantation for acute leukemia, adjusted for patient age, perfor-
mance score, cytomegalovirus serostatus, donor-recipient HLA match, blood
group ABO match, conditioning regimen, GVHD prophylaxis, donor age, and
year of transplantation.
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Figure 3. The 5-year probability of overall survival by disease status after PB
and BM transplantation for chronic myeloid leukemia, adjusted for patient age,
performance score, cytomegalovirus serostatus, donor-recipient HLA match,
blood group ABO match, conditioning regimen, GVHD prophylaxis, donor age,
and year of transplantation. Additionally, survival rates for chronic myeloid
leukemia in ﬁrst chronic phase is adjusted for tyrosine kinase inhibitor use
before transplantation and the interval from diagnosis to transplantation.
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We report on transplantation-outcomes in a large cohort
of patients with acute leukemia, MDS, and CML who un-
derwent PB or BM transplantation in 2000 to 2008. Consis-
tent with the ﬁndings of others, chronic GVHD rates were
higher andmore severe after transplantation of PB compared
with after transplantation of BM [1,8]. Antithymocyte glob-
ulin with standard GVHD prophylaxis, which has been
shown to be effective in lowering GVHD rates as well as its
severity, was used for 20% of PB and 24% of BM trans-
plantations [9-11]. Trials aimed at better GVHD prophylaxis
that is either drug mediated or through graft manipulation
are needed to lower chronic GVHD rates after PB trans-
plantation. For patients with acute leukemia, long-term
survival was comparable after transplantation of PB and
BM. Our ﬁndings are consistent with that reported after HLA-
matched sibling transplantation for acute leukemia [2,3],
except for 1 meta-analysis [12], which suggested higher
survival after transplantation of PB from HLA-matched sib-
lings for those with advanced acute leukemia. Long-term
survival was comparable after transplantation of PB and
BM for MDS but for more advanced MDS (RAEB), the pattern
of treatment failure differed by graft type. Any advantage
from fewer relapses after transplantation of PB for MDS-
RAEB was negated by higher nonrelapse mortality. On the
other hand, for good-risk CML (ﬁrst chronic phase), higher100
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Figure 2. The 5-year probability of overall survival by disease status after PB
and BM transplantation for myelodysplastic syndrome, adjusted for patient
age, performance score, cytomegalovirus serostatus, donor-recipient HLA
match, blood group ABO match, conditioning regimen, GVHD prophylaxis,
donor age, and year of transplantation.nonrelapse mortality after transplantation of PB compared
with BM resulted in lower survival and long-term after
transplantation of PB. Our ﬁndings are consistent with long-
term survival observed after HLA-matched sibling trans-
plantation [2]. In early CML, relapse rates are low with both
graft types (9% and 6%; Table 2), leaving little to gain by
higher chronic GVHD after PB transplantation, which resul-
ted in higher mortality, long-term. In contrast, for patients
with CML who underwent transplantation in second chronic,
accelerated, or blast phase, there were no signiﬁcant differ-
ences in rates of overall survival, nonrelapse mortality, or
relapse. This is different from HLA-matched sibling trans-
plantation, where mortality risks were lower using PB in
those with advanced CML. Nonrelapse mortality rates were
high with both graft types after unrelated donor trans-
plantation and in the absence of lower rates of relapse after
PB transplantation, it is not surprising we did not observe
differences in rates of survival.
Review of numbers of unrelated donor transplantation for
CML between 2000 and 2013 in the United States reported to
the Center for International Blood and Marrow Transplant
Research revealed the following: (1) there was a marked
decline in numbers of unrelated donor transplantations after
2000, which is explained by the availability of tyrosine ki-
nase inhibitors, and (2) a predominance of PB trans-
plantations. In the period between 2000 and 2002, BM was
the predominant graft, accounting for 81% of trans-
plantations. There was an increase in the use of PB grafts
beginning in 2003, which has continued to date. Between
2003 and 2008, 41% of transplantations used BM grafts and
between 2009 and 2013, only 29% used BM grafts. When
limited to CML ﬁrst chronic phase, between 2003 and 2008,
48% of transplantations used BM grafts and between 2009
and 2013, 34% of transplantations used BM grafts. The
adverse effect on survival after transplantation of PB from
HLA-matched siblings for CML in ﬁrst chronic phase was
published in 2006 [2]. Although it can be argued the data
reported were for HLA-matched sibling transplantation, the
switch to PB as the predominant graft source for unrelated
donor transplantation occurred in the absence of data to
support the switch for patients with good-risk disease.
This was not a randomized trial and, therefore, it is sub-
ject to bias owing to the complex selection criteria that un-
derlie the choice of graft for unrelated donor transplantation.
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outcomes comparing unrelated donor PB and BM trans-
plantation for hematologic malignancy with myeloablative
transplantation conditioning regimens. With the exception
of patients with CML who underwent transplantation in ﬁrst
chronic phase, long-term survival is similar to that after
transplantation of PB and BM. For CML in ﬁrst chronic phase,
lower rates of long-term survival after PB transplantation
imply that BM is the preferred graft.
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